This website contains promotional content and is intended for Healthcare Professionals in the Republic of Ireland only. Adverse event reporting can be found at the bottom of the page
{
event: "article_read",
name: `RCT Evidence on Time-In-Range in Type 1 Diabetes`,
author: `Dr Amar Puttanna`,
tags: `Diabetes`,
publication_date: ``,
interaction_type: "content"
}
Article
Source: Campus Sanofi
RCT Evidence on Time-In-Range in Type 1 Diabetes
Author :Dr Amar Puttanna
Editorial Team
Amar Puttanna - RCT Evidence
RCT Evidence on Time-In-Range in Type 1 Diabetes
Length: 13:04
Dr Amar Puttanna presents the findings from the InRange study, that compares second generation basal insulins in adults with T1DM, using Time-In-Range as the primary endpoint.
Recommended Videos
Practicalities of Supporting the Teenager with Type 2 Diabetes | Toujeo® (insulin glargine 300 units/mL)
What Insulins Do I Need In My Toolbox To Support People With Type 2 Diabetes | Toujeo® (insulin glargine 300 units/mL) | Lantus® (insulin glargine 100 units/mL)
You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.
This site is intended for Healthcare Professionals in the Republic of Ireland and contains information on Sanofi Ireland medicine, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a Healthcare Professional in the Republic of Ireland. This site contains promotional information.
.jpg/jcr:content.jpg){kind=logo}
